U.S. markets open in 2 hours 6 minutes
  • S&P Futures

    4,293.00
    -5.25 (-0.12%)
     
  • Dow Futures

    33,850.00
    -23.00 (-0.07%)
     
  • Nasdaq Futures

    13,666.25
    -15.00 (-0.11%)
     
  • Russell 2000 Futures

    2,021.70
    -2.10 (-0.10%)
     
  • Crude Oil

    89.42
    +0.01 (+0.01%)
     
  • Gold

    1,790.50
    -7.60 (-0.42%)
     
  • Silver

    20.02
    -0.25 (-1.22%)
     
  • EUR/USD

    1.0131
    -0.0034 (-0.33%)
     
  • 10-Yr Bond

    2.7910
    0.0000 (0.00%)
     
  • Vix

    20.06
    +0.53 (+2.71%)
     
  • GBP/USD

    1.2025
    -0.0033 (-0.28%)
     
  • USD/JPY

    134.4060
    +1.1340 (+0.85%)
     
  • BTC-USD

    24,101.74
    -128.48 (-0.53%)
     
  • CMC Crypto 200

    574.24
    -16.52 (-2.80%)
     
  • FTSE 100

    7,556.82
    +47.67 (+0.63%)
     
  • Nikkei 225

    28,868.91
    -2.87 (-0.01%)
     

ENDRA Life Sciences to Present at H.C. Wainwright Virtual BioConnect 2021 Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ANN ARBOR, MI / ACCESSWIRE / January 8, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that Chairman and CEO Francois Michelon will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021. The presentation can be accessed here and on the Investor Relations section of the ENDRA website beginning on January 11, 2021 at 6:00 a.m. Eastern time and will be archived for 90 days.

About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with the over 1 million ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Investor Relations Contact:
Kim Sutton Golodetz
LHA Investor Relations
(212) 838-3777
kgolodetz@lhai.com

SOURCE: ENDRA Life Sciences Inc.



View source version on accesswire.com:
https://www.accesswire.com/623551/ENDRA-Life-Sciences-to-Present-at-HC-Wainwright-Virtual-BioConnect-2021-Conference